WHAT WE CAN DO FOR YOUR PRODUCTS:
AMNOG is the German interpretation of the global megatrend for more evidence in reimbursement decisions of health technologies (Health Technology Assessment (HTA)). The support of Market Access is substantially more than ‘just’ AMNOG: Reimbursement of new products inpatient and outpatient, e.g. by NUB-applications, DRG workshops, applications for OPS codes, preparation of internationally harmonized/coordinated Market Access strategies, analysis of reference pricing, contracting models with payers and insurance companies, development and performance of ‘Sounding Boards’ for fruitful discussions with decision makers as well as interviews with selected stakeholders. For the upcoming negotiations during the Market Access process, we provide you with perfectly matching contacts and offer customized training, as well as our support during the process of negotiations and decision making. The monitoring and evaluation of results and measures is a matter of course for SmartStep.